Schizophrenia
Conditions
Keywords
psychosis, cognition
Brief summary
The purpose of this study is to test the safety and effectiveness of talnetant vs. risperidone vs. placebo in reducing positive and negative symptoms in acutely psychotic schizophrenia patients.
Interventions
DRUGTalnetant
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Subjects must have schizophrenia which is not secondary to another medical condition or substance abuse. * Require inpatient hospitalization. * Women may enroll only if they are not of child-bearing potential OR are on a protocol-approved birth control method.
Exclusion criteria
* Subject is in their first episode of schizophrenia. * Subject has other psychotic disorders or bipolar disorder. * Subject has schizophrenia symptoms from taking another medicine or drug of abuse, or due to a general medical condition. * Subject has a recent history of substance dependence, or tests positive for illicit drug. * Subject has an unstable medical disorder, or any significant medical disorder including autistic disorder, organic brain disease, liver dysfunction, epilepsy or seizures, or is at increased risk of developing cerebrovascular problems like stroke. * Subject has any significant abnormalities in any of the screening tests (ECGs, labs, physical examinations, etc.). * Subject poses a current serious suicidal or homicidal risk. * Subject has a positive pregnancy test, or is lactating or planning to become pregnant within one month of the study. * Subject has recently or is currently participating in another clinical study. * Subject is stabilized on their current schizophrenia treatment. * Subject needs to take any of the medicines not permitted in the study, or has recently had ECT (electroconvulsive therapy) or TMS (transcranial magnetic stimulation). * Subject was non-responsive to two or more adequate trials of antipsychotic treatments over the past 2 years. * Subject has had an allergic or significant reaction to any of the study drugs, or can't take risperidone.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome measure is change in the Positive and Negative Syndrome Scale (PANSS) at Week 6 compared to baseline values. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary measures assess both efficacy (cognition, depression) as well as a variety of safety/tolerability endpoints (adverse events, motor function, laboratory measures). | — |
Countries
United States
Outcome results
None listed